Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0WK8I
|
|||
| Drug Name |
Sulfonylated piperazine derivative 2
|
|||
| Synonyms |
PMID26161824-Compound-182
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Obesity [ICD-11: 5B81; ICD-10: E66; ICD-9: 278] | Patented | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C23H28N2O3S
|
|||
| Canonical SMILES |
C1CCC(CC1)C(=O)N2C3CCC2CN(C3)S(=O)(=O)C4=CC=CC5=CC=CC=C54
|
|||
| InChI |
1S/C23H28N2O3S/c26-23(18-8-2-1-3-9-18)25-19-13-14-20(25)16-24(15-19)29(27,28)22-12-6-10-17-7-4-5-11-21(17)22/h4-7,10-12,18-20H,1-3,8-9,13-16H2
|
|||
| InChIKey |
REHIEVFQRQVSNB-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cannabinoid receptor 1 (CB1) | Target Info | Antagonist | [1] |
| Target's Patent Info | Cannabinoid receptor 1 (CB1) | Target's Patent Info | [1] | |
| KEGG Pathway | Rap1 signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Retrograde endocannabinoid signaling | ||||
| Panther Pathway | Endogenous cannabinoid signaling | |||
| Pathway Interaction Database | N-cadherin signaling events | |||
| Reactome | Class A/1 (Rhodopsin-like receptors) | |||
| G alpha (i) signalling events | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Small Ligand GPCRs | ||||
| BDNF signaling pathway | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| GPCRs, Other | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.